Jacobs Levy Equity Management Inc. Sells 30,116 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Jacobs Levy Equity Management Inc. lowered its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 504,545 shares of the company’s stock after selling 30,116 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in iTeos Therapeutics were worth $6,882,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ITOS. Vanguard Group Inc. increased its position in shares of iTeos Therapeutics by 2.3% during the third quarter. Vanguard Group Inc. now owns 1,813,759 shares of the company’s stock worth $19,861,000 after buying an additional 40,407 shares during the period. Acadian Asset Management LLC acquired a new stake in iTeos Therapeutics in the first quarter worth $3,337,000. Vontobel Holding Ltd. grew its holdings in iTeos Therapeutics by 41.9% in the fourth quarter. Vontobel Holding Ltd. now owns 220,056 shares of the company’s stock worth $2,410,000 after purchasing an additional 64,981 shares during the period. Sectoral Asset Management Inc. grew its holdings in iTeos Therapeutics by 41.9% in the fourth quarter. Sectoral Asset Management Inc. now owns 220,056 shares of the company’s stock worth $2,410,000 after purchasing an additional 64,981 shares during the period. Finally, Kennedy Capital Management LLC bought a new position in shares of iTeos Therapeutics in the first quarter valued at $1,988,000. Institutional investors own 97.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on ITOS shares. HC Wainwright raised their price objective on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Wedbush reissued an “outperform” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research report on Monday, June 17th.

iTeos Therapeutics Stock Performance

ITOS stock traded up $0.13 during mid-day trading on Tuesday, hitting $17.47. The company had a trading volume of 230,961 shares, compared to its average volume of 349,984. iTeos Therapeutics, Inc. has a 12 month low of $8.20 and a 12 month high of $18.75. The stock’s fifty day moving average price is $16.15 and its two-hundred day moving average price is $13.24.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Friday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.05). As a group, equities analysts forecast that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.